---
title: "Core Healthcare Ltd (COREPARENT) — Share Price, Financials & Analysis"
symbol: "COREPARENT"
company: "Core Healthcare Ltd"
canonical: "https://tapetide.com/stocks/COREPARENT"
nse_symbol: "COREPARENT"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:36:22.933Z"
---

# Core Healthcare Ltd (COREPARENT)

Canonical page: https://tapetide.com/stocks/COREPARENT

## Company

- **NSE Symbol:** COREPARENT
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** corehealthcare.com

## Latest Price

## Key Insights

### Strengths

- Company has reduced debt.

## Growth Rates

| Metric | 1Y |
| --- | --- |
| net income growth | 129% |
| revenue growth | -100% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- | --- |
| Sales | 69 | 62 | 68 | 66 | 78 |
| Expenses | 58 | 56 | 61 | 59 | 72 |
| Operating Profit | 11 | 6 | 7 | 7 | 6 |
| OPM % | 16 | 9 | 10 | 10 | 8 |
| Other Income | -1 | 2 | 1 | 1 | 2 |
| Interest | 1 | 2 | 1 | 2 | 3 |
| Depreciation | 1 | 1 | 1 | 2 | 3 |
| Profit before tax | 8 | 6 | 6 | 4 | 2 |
| Tax % | 25 | 32 | 0 | 59 | 0 |
| Net Profit | 6 | 4 | 6 | 1 | 2 |
| EPS in Rs | 4.75 | 2.24 | 3.34 | 0.84 | 1.36 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 |
| --- | --- | --- |
| Sales | 38.58 | 0 |
| Expenses | 60.22 | 8.47 |
| Operating Profit | -21.64 | -8.47 |
| OPM % | -56.09 | — |
| Other Income | 1.6 | -0.2 |
| Interest | 1.53 | 0.03 |
| Depreciation | 43.3 | 1.13 |
| Profit before tax | -64.87 | -9.83 |
| Tax % | 0.03 | 0.1 |
| Net Profit | -64.89 | -9.84 |
| Dividend Payout % | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 |
| --- | --- | --- |
| Equity Capital | 33.99 | 33.99 |
| Reserves | -1060.06 | -177.34 |
| Borrowings | 1844.87 | 151.31 |
| Other Liabilities | 55.37 | 6.11 |
| Total Liabilities | 874.17 | 14.07 |
| Fixed Assets | 481.23 | 13.26 |
| CWIP | 70.65 | 0 |
| Investments | 41.1 | 0 |
| Other Assets | 281.19 | 0.81 |
| Total Assets | 874.17 | 14.07 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 |
| --- | --- | --- |
| Cash from Operating Activity | -3.21 | -5.09 |
| Cash from Investing Activity | -1.16 | 2.65 |
| Cash from Financing Activity | 3.07 | 0.5 |
| Net Cash Flow | -1.3 | -1.94 |
| Free Cash Flow | -5.51 | -4.55 |
| CFO/OP | 15 | 60 |

### Ratios

| Item | Mar 2006 | Mar 2007 |
| --- | --- | --- |
| Debtor Days | 21.95 | — |
| Inventory Days | 2.04 | — |
| Days Payable | 31.87 | — |
| Cash Conversion Cycle | -7.87 | — |
| Working Capital Days | -2.46 | — |
| ROCE % | — | 4.5 |

## Shareholding Pattern

### annual

| Category | Mar 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- |
| Promoters | 69.98% | 69.98% | 69.98% |
| FIIs | 5.81% | 0.06% | 0% |
| DIIs | 1.93% | 0% | 0% |
| Public | 22.28% | 29.96% | 30.02% |
| No. of Shareholders | 1117 | 1544 | 1466 |

### Quarterly

| Category | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- |
| Promoters | 69.98% | 69.98% | 69.98% | 69.98% |
| FIIs | 5.81% | 0.42% | 0.06% | 0% |
| DIIs | 1.93% | 0% | 0% | 0% |
| Public | 22.28% | 29.6% | 29.96% | 30.02% |
| No. of Shareholders | 1117 | 1355 | 1544 | 1466 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 0 / 7 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 58.41 | Sell |
| EMA (10) | 58.4 | Sell |
| SMA (20) | 61.66 | Sell |
| EMA (20) | 60.29 | Sell |
| SMA (50) | 61.34 | Sell |
| EMA (50) | 62.95 | Sell |
| SMA (100) | 67.5 | Sell |
| EMA (100) | 68.04 | Sell |
| SMA (200) | 80.39 | Sell |
| EMA (200) | 76.21 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 39.15 | Neutral |
| MACD (12,26,9) | -2.02 | Sell |
| Stochastic (14,3,3) | 28.68 | Neutral |
| ADX (14) | 19.57 | Neutral |
| Williams %R (14) | -69.06 | Neutral |
| ATR (14) | 4.02 | High Volatility |
| ROC (12) | -11.61 | Sell |
| Stoch RSI (14) | 27.76 | Neutral |
| UO (7,14,28) | 55.46 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 6 February 2026 - Awarded tender by MPPHCL to supply Itraconazole capsules; order value ₹87.98 Lacs (06-Feb-2026). | [General Updates 6 February 2026 - Awarded tender by MPPHCL to supply Itraconazole capsules; order value ₹87.98 Lacs (06-Feb-2026).](https://nsearchives.nseindia.com/corporate/ZENITH_06022026135415_News_Update.pdf) |
| 5 February 2026 - Clarifies IPO proceeds Rs.3,595.55 lakhs fully utilized by Sep 30, 2024; revised deviation filed Nov 14, 2024. | [Reply to Clarification- Financial results 5 February 2026 - Clarifies IPO proceeds Rs.3,595.55 lakhs fully utilized by Sep 30, 2024; revised deviation filed Nov 14, 2024.](https://nsearchives.nseindia.com/corporate/ZENITH_14012026120856_Clarification_Letter.pdf) |
| 30 January 2026 - Awarded MP Public Health tender to supply Povidone Iodine 5% (500ml); order value ~₹1.46 Crore (Jan 30, 2026). | [General Updates 30 January 2026 - Awarded MP Public Health tender to supply Povidone Iodine 5% (500ml); order value ~₹1.46 Crore (Jan 30, 2026).](https://nsearchives.nseindia.com/corporate/ZENITH_30012026124601_News_Update.pdf) |
| 13 January 2026 - Exchange has sought clarification from Zenith Drugs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On … | [Clarification - Financial Results 13 January 2026 - Exchange has sought clarification from Zenith Drugs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …](https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=ZENITHDRUG&tabIndex=sme) |
| 10 February 2026 - GMP Certificate under Revised Schedule ‘M’ issued after 02 Feb 2026 inspection; valid till 12 Sep 2028. | [General Updates 10 February 2026 - GMP Certificate under Revised Schedule ‘M’ issued after 02 Feb 2026 inspection; valid till 12 Sep 2028.](https://nsearchives.nseindia.com/corporate/ZENITH_10022026135758_News_Update.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28447_ZENITHDRUG_2024_2025_A_13178144_04092025181334.pdf) |
| from nse | [Financial Year 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_26279_ZENITHDRUG_2023_2024_0210202411248.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:36:22.933Z.